logo
episode-header-image
Nov 2021
2h 2m

#185 - Allan Sniderman, M.D.: Cardiovasc...

Peter Attia, MD
About this episode

Allan Sniderman is a highly acclaimed Professor of Cardiology and Medicine at McGill University and a foremost expert in cardiovascular disease (CVD). In this episode, Allan explains the many risk factors used to predict atherosclerosis, including triglycerides, cholesterol, and lipoproteins, and he makes the case for apoB as a superior metric that is currently being underutilized. Allan expresses his frustration with the current scientific climate and its emphasis on consensus and unanimity over encouraging multiple viewpoints, thus holding back the advancement of metrics like apoB for assessing CVD risk, treatment, and prevention strategies. Finally, Allan illuminates his research that led to his 30-year causal model of risk and explains the potentially life-saving advantages of early intervention for the prevention of future disease. We discuss:

  • Problems with the current 10-year risk assessment of cardiovascular disease (CVD) and the implications for prevention [4:30];
  • A primer on cholesterol, apoB, and plasma lipoproteins [16:30];
  • Pathophysiology of CVD and the impact of particle cholesterol concentration vs. number of particles [23:45];
  • Limitations of standard blood panels [29:00];
  • Remnant type III hyperlipoproteinemia—high cholesterol, low Apo B, high triglyceride [32:15];
  • Using apoB to estimate risk of CVD [37:30];
  • How Mendelian randomization is bolstering the case for ApoB as the superior metric for risk prediction [40:45];
  • Hypertension and CVD risk [49:15];
  • Factors influencing the decision to begin preventative intervention for CVD [58:30];
  • Using the coronary artery calcium (CAC) score as a predictive tool [1:03:15];
  • The challenge of motivating individuals to take early interventions [1:12:30];
  • How medical advancement is hindered by the lack of critical thinking once a “consensus” is reached [1:15:15];
  • PSK9 inhibitors and familial hypercholesterolemia: two examples of complex topics with differing interpretations of the science [1:20:45];
  • Defining risk and uncertainty in the guidelines [1:26:00];
  • Making clinical decisions in the face of uncertainty [1:31:00];
  • How the emphasis on consensus and unanimity has become a crucial weakness for science and medicine [1:35:45];
  • Factors holding back the advancement of apoB for assessing CVD risk, treatment, and prevention strategies [1:41:45];
  • Advantages of a 30-year risk assessment and early intervention [1:50:30];
  • More.
Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/AllanSniderman  Subscribe to receive exclusive subscriber-only content:  https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.
Up next
Jul 7
Navigating bone health: early life influences and advanced strategies for improvement and injury prevention (#214 rebroadcast)
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this episode from July 2022, Peter dives deep into the topic of bone health and explains why this is an important topic for everyone, from childr ... Show More
1h 31m
Jun 30
#355 – Skincare strategies, the science of facial aging, and cosmetic-intervention guidance | Tanuj Nakra, M.D. & Suzan Obagi, M.D.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Tanuj Nakra and Suzan Obagi, two leading experts in aesthetic medicine, join Peter to explore the science of facial aging and skin health as well as ... Show More
2h 57m
Jun 23
#354 – What the dying can teach us about living well: lessons on life and reflections on mortality | BJ Miller, M.D. and Bridget Sumser, L.C.S.W.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter BJ Miller, a hospice and palliative care physician, and Bridget Sumser, a licensed social worker specializing in serious illness and end-of-life car ... Show More
2h 16m
Recommended Episodes
Dec 2023
#085 Dr. Peter Attia on Mastering Longevity – Insights on Cancer Prevention, Heart Disease, and Aging
Download the 9-Page "Cognitive Enhancement Blueprint" Discover my premium podcast The Aliquot Show notes are available by clicking here Peter Attia, MD is a highly respected expert in preventive medicine, focused on the crucial subject of longevity and cardiovascular health. He's ... Show More
3h 59m
Jul 2022
224. Atrial Fibrillation: Assessment of Stroke & Bleeding Risk with Dr. Elaine Hylek
CardioNerds (Amit Goyal), Dr. Colin Blumenthal (CardioNerds Academy House Faculty Leader and FIT at the University of Pennsylvania), and Dr. Anjali Wagle (CardioNerds Ambassador and FIT at Johns Hopkins University), discuss the baseline assessment of stroke and bleeding risk in p ... Show More
1h 15m
Jul 2022
217. Guidelines: 2021 ESC Cardiovascular Prevention – Question #14 with Dr. Allison Bailey
The following question refers to Sections 3.3-3.4 of the 2021 ESC CV Prevention Guidelines. The question is asked by student Dr. Adriana Mares, answered first by early career preventive cardiologist Dr. Dipika Gopal, and then by expert faculty Dr. Allison Bailey. Dr. Bailey is a ... Show More
11m 55s
Aug 2023
326. Guidelines: 2021 ESC Cardiovascular Prevention – Question #32 with Dr. Michael Wesley Milks
The following question refers to Section 3.4 of the 2021 ESC CV Prevention Guidelines. The question is asked by student Dr. Adriana Mares, answered first by early career preventive cardiologist Dr. Dipika Gopal, and then by expert faculty Dr. Michael Wesley Milks. Dr. Milks is a ... Show More
9m 51s
Dec 2022
158 - PADing Your Understanding of Peripheral Arterial Disease: A Brief Treatment Overview
In this episode, we will discuss all things peripheral arterial disease – definitions, staging, clinical presentation, risk factors, goals of therapy, and guideline-directed medication therapy recommendations including the newest evidence for the use of DOACs. Key Concepts Addres ... Show More
49m 23s
Oct 2023
341. Guidelines: 2021 ESC Cardiovascular Prevention – Question #35 with Dr. Melissa Tracy
The following question refers to Section 4.9 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Christian Faaborg-Andersen, answered first by UCSD fellow Dr. Patrick Azcarate, and then by expert faculty Dr. Melissa Tracy. Dr. Tracy is a preventive cardiologist ... Show More
7m 5s
Feb 2024
AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF
Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke.  The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patie ... Show More
13m 33s
Mar 2023
Dr. Peter Attia: Improve Vitality, Emotional & Physical Health & Lifespan
In this episode, my guest is Peter Attia, M.D. He completed his medical and advanced training at Stanford University School of Medicine, Johns Hopkins School of Medicine and the National Institutes of Health (NIH). Dr. Attia is host of the health and medicine podcast, The Drive, ... Show More
3h 25m
Jan 2024
ACCEL Lite: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
While we know that statin treatment reduces the risk of stroke, heart attack and heart deaths in people at moderate-to-high risk, or with high cholesterol, in REPRIEVE statins decreased the risk in those at low-to-moderate risk, and with 'normal' cholesterol levels who would not ... Show More
11m 46s
Jun 2024
#525: Cholesterol-Lowering Medication – Dr. Paddy Barrett
Cholesterol-lowering medications, particularly statins, play a pivotal role in reducing low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) concentrations, which are causal markers in atherosclerosis development. The efficacy of these medications is well-docum ... Show More
48m 29s